Robert Hazlett
Stock Analyst at BTIG
(1.96)
# 3,550
Out of 5,176 analysts
22
Total ratings
38.89%
Success rate
5.07%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.48 | +270.37% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $72.08 | -16.76% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.14 | +1,128.07% | 2 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $161.78 | -39.42% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.09 | +1,078.78% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $5.62 | +1,021.00% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.31 | +211.49% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $0.89 | +2,921,576.59% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.39 | +331.65% | 2 | Sep 4, 2020 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $18 | $17.14 | +5.02% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.48
Upside: +270.37%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $72.08
Upside: -16.76%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.14
Upside: +1,128.07%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $161.78
Upside: -39.42%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.09
Upside: +1,078.78%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $5.62
Upside: +1,021.00%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.31
Upside: +211.49%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $0.89
Upside: +2,921,576.59%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.39
Upside: +331.65%
KalVista Pharmaceuticals
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $17.14
Upside: +5.02%